MARY PRIBOR: Open Payments
NPI 1558907139 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,818 in 127 payments from 20 companies in 2025. Trend: 2023 $107 · 2024 $863 · 2025 $2,818
Food & beverage: $2,746Education: $72
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 28 | $618 |
| Incyte Corporation | 22 | $467 |
| GENZYME CORPORATION | 12 | $346 |
| ABBVIE INC. | 17 | $305 |
| Regeneron Healthcare Solutions, Inc. | 11 | $178 |
| Novartis Pharmaceuticals Corporation | 7 | $176 |
| LEO Pharma Inc. | 6 | $108 |
| UCB, Inc. | 3 | $90 |
| Arcutis Biotherapeutics, Inc. | 4 | $80 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $80 |
Products named: TREMFYA, DUPIXENT, OPZELURA, COSENTYX, RINVOQ, SKYRIZI, Bimzelx, Zoryve.
Industry payments across NY — which companies pay providers there.
